M&A Deal Summary |
|
|---|---|
| Date | 2012-10-18 |
| Target | Presidio Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | BioCryst Pharmaceuticals |
| Sellers(s) |
Bay City Capital
NMT Capital |
| Deal Type | Merger |
| Deal Value | 101M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1986 |
| Sector | Life Science |
| Employees | 536 |
| Revenue | 331M USD (2023) |
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst Pharmaceuticals was incorporated in 1986 and is based in Durham, North Carolina.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Merger) | 1 of 1 |
| State (California) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2012) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 1.3B USD |
| Size | Large |
| Type | Sector Focused |
Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 39 of 62 |
| Sector (Life Science) | 26 of 45 |
| Type (Merger) | 1 of 4 |
| State (California) | 20 of 33 |
| Country (United States) | 37 of 59 |
| Year (2012) | 4 of 5 |
| Size (of disclosed) | 14 of 18 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-07-26 |
Hyperion Therapeutics
Brisbane, California, United States Hyperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-10-22 |
NextWave Pharmaceuticals
Cupertino, California, United States NextWave Pharmaceuticals is a specialty pharmaceutical company developing extended release OTC and prescription products for children and adults. NextWave Pharmaceuticals was founded in 2005 and is based in Cupertino, California. |
Sell | $700M |
| Category | Private Equity Firm |
|---|---|
| Size | Small |
| Type | Sector Agnostic |
NMT Capital is a private equity firm focused on tech-oriented growth industries. Areas of interest include medical devices, diagnostics, biotechnology, specialty pharmaceutical, drug discovery tools, software, communications, information technology, and advanced materials. NMT Capital is based in Quincy, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 10 |
| Sector (Life Science) | 2 of 2 |
| Type (Merger) | 1 of 1 |
| State (California) | 1 of 2 |
| Country (United States) | 3 of 8 |
| Year (2012) | 2 of 2 |
| Size (of disclosed) | 3 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-05-23 |
Kiyatec
Greenville, South Carolina, United States Kiyatec is commercializing novel 3D cell culture technology, developed at Clemson University, and is providing tools for researchers and clinicians with advanced in vitro models for improved understanding in cell and systems biology, drug development, and clinical diagnosis. Kiyatec was founded in 2005 and is based in Greenville, South Carolina. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-03-20 |
Selah Genomics
Greenville, South Carolina, United States Selah Genomics is a clinical diagnostic company that is rapidly growing at the cutting edge of molecular analysis and next generation sequencing (NGS), and is emerging as a leader in the development of personalized medicine. |
Sell | $70M |
